stock delisting
Nasdaq Panel Delisting T2 Biosystems Stock
The company was in violation of the stock exchange's requirements for the minimum bid price and the market value of listed securities.
Nasdaq Affirms OpGen's Delisting Decision
The molecular diagnostics developer has appealed the decision and said its stock will continue to trade on the OTC markets in the meantime.
T2 Biosystems Receives Delisting Notice From Nasdaq
The company has requested a hearing and paid a $20,000 fee to delay its delisting determination until Jan. 9, 2025.
OpGen Shares Suspended From Trading on Nasdaq
The suspension comes as the molecular diagnostics firm struggles to meet the Nasdaq's minimum stockholders’ equity requirement.
OpGen Submits Plan to Nasdaq After Missing Another Listing Requirement
The company has struggled to stay afloat after the bankruptcy of its European subsidiaries and the sale of most of its remaining assets.
Apr 24, 2024
Nasdaq Warns OpGen About Overdue 2023 Annual Report
Apr 17, 2024
DermTech Receives Delisting Warning From Nasdaq
Jan 7, 2024
LumiraDx Shares to be Delisted From Nasdaq
Jan 4, 2024
Burning Rock Receives Nasdaq Delisting Warning
Dec 13, 2023
OpGen Requests Hearing on Nasdaq Delisting
Nov 27, 2023
T2 Biosystems Receives Nasdaq Delisting Notice
Sep 25, 2023
Invitae Warned by NYSE of Noncompliance
Jan 23, 2023
AnPac Bio Receives Nasdaq Delisting Notice
Mar 28, 2022
AnPac Bio Receives Nasdaq Delisting Notice
Apr 9, 2020